Moreover, meta-analytic data demonstrate that SGLT2 inhibition reduces the risk of cardiovascular death or HF hospitalization by 23% regardless of LVEF [45], raising the possibility of synergistic benefits when combined with iron repletion. Here, SLC5A2 is linked to hydrops fetalis.